BMEA Biomea Fusion Inc
Company Analysis
Latest News
Biomea Fusion Bets Its Future on an Obesity Pill — But Can a $100 Million Company Compete With Eli Lilly?
Shares shifted as Biomea Fusion surged 8.1% in pre-market trading to $1.47, fueled by anticipation of Phase I clinical data for its experimental oral...
🟢 Biomea Fusion is trading 8.1% up in pre-market ahead of scheduled BMF-650 Phase I results
Biomea Fusion is trading at $1.47, up 8.11% pre-market ahead of its planned Phase I results update for BMF-650. - On October 12, Biomea Fusion announced it...
🟢 Biomea Fusion is trading 16.18% up in after-hours trading with no clear catalyst
Biomea Fusion is trading at $1.58, up 16.18% in after-hours trading, with no clear catalyst identified. - No clear company-specific announcement on October 12...
🟢 Biomea Fusion is trading 5% up today amid broader biotech-sector strength
Biomea Fusion is trading 5.11% higher at $1.44 on October 9, 2026, with no clearly reported company-specific catalyst; biotech-sector strength provides broader...
🟢 Biomea Fusion is trading 5% up with no clear catalyst
Biomea Fusion is trading at $1.31, up 5.20% during the October 7 session, with no clear company-specific catalyst identified. - Biomea Fusion’s latest listed...
🟢 Biomea Fusion is trading 6% up today amid broader market gains
Biomea Fusion is trading at $1.33, up 5.56%, with broader market strength potentially supporting the gain. - No clear company-specific announcement explaining...
🟢 Biomea Fusion is trading 6.1% up in pre-market with no clear catalyst identified
Biomea Fusion is trading 6.1% up at $1.40 in pre-market on September 28; available evidence does not establish a specific cause. - The recent clinical-data...
🔴 Biomea Fusion is trading 10% down today after BMF-650 readout shifted to October 2026
Biomea Fusion is trading at $1.34, down 10.07%, after investors reacted to the BMF-650 Phase I topline readout being delayed from the third quarter to October...
🔴 Biomea Fusion is trading 5.7% down today after BMF-650 topline results delayed to October
Biomea Fusion is trading 5.7% lower at $1.41 as investors await BMF-650 Phase I topline results, delayed to October 2026. - Results were previously expected in...
🔴 Biomea Fusion is trading 11.18% down today after terminating proposed public offering
Biomea Fusion is trading 11.18% down at $1.51 after terminating its proposed public offering on September 23, 2026. - Management said market conditions were...
🔴 Biomea Fusion is trading 6.18% down today as dilution concerns persist after offering termination
Biomea Fusion is trading 6.18% down at $1.59 as dilution and financing concerns persist after it terminated its proposed offering. - On September 22, 2026,...
Biomea Fusion's Fire Sale: Can a Cash-Starved Biotech Survive Long Enough to Prove Its Pipeline?
Shares cratered as Biomea Fusion disclosed a new stock offering that threatens to shrink existing investors' stakes — right before the company's most critical...
🔴 Biomea Fusion is trading 15.28% down in pre-market after announcing proposed stock and warrant offering
Biomea Fusion is trading 15.28% lower at $1.44 after announcing a proposed underwritten public offering of common stock and pre-funded warrants on September...
🔴 Biomea Fusion is trading 16.79% down in after-hours trading with no identified company-specific catalyst
Biomea Fusion is trading 16.79% down at $1.41 in after-hours trading, after closing at $1.71 on September 22, 2026; no clear company-specific catalyst was...
🔴 Biomea Fusion is trading 6.28% down today with no clear catalyst identified
Biomea Fusion is trading at $1.72, down 6.28% during early trading on September 21, 2026, with no fresh company-specific catalyst identified. - No fresh...
🟢 Biomea Fusion is trading 5.87% up today amid broader biotech-sector advance
Biomea Fusion is trading 5.87% up now at $1.90, following a broader biotechnology-sector advance rather than a confirmed company-specific catalyst. - Biotech...
🔴 Biomea Fusion is trading 6.3% down in pre-market with no confirmed catalyst
Biomea Fusion is trading at $1.63 (-6.32%) with no confirmed catalyst identified. - No newly reported company-specific announcement appeared on September 16...
🔴 Biomea Fusion is trading 5% down today after disappointing pelacarsen trial results from Ionis Pharmaceuticals
Biomea Fusion is trading 5.06% down now at $1.69 after opening lower amid a broader biotech selloff tied to disappointing pelacarsen trial results from Ionis...
🟢 Biomea Fusion is trading 5.88% up in pre-market as major U.S. indices rise
Biomea Fusion is trading 5.88% up at $1.80, aligned with broader pre-market risk appetite as major U.S. indices are each up more than 0.5%. - It closed at...
🟢 Biomea Fusion is trading 5.9% up in after-hours trading, with no clear company-specific explanation
Biomea Fusion is trading 5.9% up at $1.80 after closing September 10, 2026 at $1.70, with no clear company-specific announcement or earnings release explaining...